Biotech leadership
Which assets, indications or partnerships deserve scarce development resources?
Relevant engagement
Portfolio & Competitive StrategyIndependent life sciences advisory
Scientific depth. Commercial clarity.
Independent strategy and scientific advisory for biotech, pharma and digital health.
Berlin-based · International engagements · Selected independent advisory
Dr. Dennis Kwiatkowski
Biochemist · Strategist · Business development advisor
- oncology assets screened
- 1,200+
- pharma engagements led
- Multiple six-figure
- biochemistry and protein science
- PhD
- bridging research and strategy
- Science → decisions
Selected experience
Experience across scientific research, life sciences consulting and pharma-facing digital health.
01
2024–presentTemedica
Pharma partnerships · RWE and digital health
02
2021–2024Scitaris
Biotech and pharma strategy consulting
03
2015–2020Charité and Freie Universität Berlin
Doctoral research · biochemistry and biophysics
04
Before 2015Bayer HealthCare
Industry structural-biology research
Core engagements
Focused expertise. Defined deliverables.
Engage me for a discrete evidence review, strategic assessment or advisory workstream—with clear outputs, timing and decision criteria.
01
Scientific & Clinical Due Diligence
Assess scientific rationale, clinical evidence, differentiation and development risk before an investment, partnership or portfolio decision.
02
Portfolio & Competitive Strategy
Clarify the competitive landscape, buyer priorities and value proposition behind development, licensing and partnership decisions.
03
Evidence & Digital Health Advisory
Translate scientific evidence, real-world data and patient perspectives into credible product, evidence and commercial decisions.
Who I work with
Different stakeholders. Specific decisions.
Life sciences investors
Is the scientific and clinical evidence strong enough to support an investment thesis?
Relevant engagement
Scientific & Clinical Due DiligencePharma-facing digital health teams
How can evidence and patient insights support a credible, fundable pharma use case?
Relevant engagement
Evidence & Digital Health AdvisoryIndependent by design
Senior attention without unnecessary layers.
You work directly with me from scoping through the analytical work and recommendation. The engagement is built around your decision—not a predefined team structure.
- Direct senior involvement and clear accountability
- Defined scope, work products and decision criteria
- Transparent timeline and commercial terms
- Specialist support only when separately scoped and agreed
Selected outcomes
Selected work. Specific questions. Actionable answers.
Examples of the questions addressed, analyses delivered and decisions supported. Client and asset details remain confidential.
Business development and licensing
1,200+ assets · 2022
Oncology asset screen for an in-licensing pipeline
An asset screen for a confidential EU biotech moved from database review to prioritization, deep dives, and due diligence.
Read this case studyPortfolio strategy
2 engagements · 2023
Radiopharmaceutical portfolio assessment and prioritization
Every clinical and preclinical program in scope was assessed systematically for a confidential US radiopharma biotech.
Read this case studyDigital health and real-world evidence
Multiple six-figure deals
Pharma data and digital health account development
As sole account owner, I led opportunities with German affiliates of multinational pharmaceutical companies from account plan to contracted scope.
Read this case studyVentures and advisory roles
Building and advising beyond client projects.
I also work on ventures in life sciences, digital health and cross-border business. These activities inform how I assess products, customers and execution risk.
Explore ventures and investmentsFounder and investor
Berlin Sofia Partners
Selected technology and healthcare investments.
Platform operator
StartinBG
Information for cross-border founders evaluating Bulgaria.
Founder
acneinversa.life
Evidence-informed patient education for hidradenitis suppurativa.
Independent advisor
Orbion
Commercial positioning for life-sciences AI workflows.
Working model
A clear process, from question to decision.
01
Frame
Agree on the decision to support, deliverables, timeline and success criteria.
02
Compare
Analyze the evidence, competing options and material uncertainties.
03
Recommend
Deliver a concise recommendation, supporting analysis and key risks.
04
Support
Support implementation or a follow-on workstream where useful.
Background
Scientific rigor with a commercial perspective.
I combine doctoral and postdoctoral research with biotech strategy consulting and pharma-facing digital health experience—connecting technical depth to practical business decisions.
Read about my experience“I can confidently say he is one of the most dedicated and skilled consultants I’ve worked with. Dennis has a strong scientific mindset, and his analytical skills are exceptional; he has a knack for digging deep into data and uncovering insights that others might miss.”
“As a Consultant at Scitaris, Dr. Kwiatkowski has shown a range of technical, organizational, and interpersonal skills to deliver his work packages efficiently and successfully. He continuously demonstrates impressive knowledge of drug development, earning the admiration and respect of both subordinates and superiors alike.”
“Dennis is an excellent sparring partner when digital health startups and pharmaceutical companies need to find common ground. He makes complex topics tangible and shares practical experience openly.”
Start with a defined scope